Inclusion Criteria:

• Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L&D unit

• Determined to be at least 23 and 0/7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery

• Consents to participation and must understand/read/speak English with the ability to understand and willingness to sign a written informed consent in English

• Diagnosed with a hypertensive pregnancy by either of the following criteria:

  • Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission
  • Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record
  • Antihypertensive" can be any medication taken for the purpose of blood pressure control per the medical record
  • A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery

• Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document.

• Has two or more blood pressures ≥160/110 Millimeters of mercury (mmHg) at least 60 minutes apart

  • If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg/ml), participants are eligible to participate)

Exclusion Criteria:

• Non-English speaking
• Ongoing pregnancy
• Stated desire to become pregnant within 8 months post-delivery
• Intention to breastfeed after enrollment
• BNP ≥1000 pg/ml within 12 hours of delivery, clinical team to be notified of result
• Comorbidities that may affect cardiovascular risk assessment (per protocol)
• Contraindication to dapagliflozin (per protocol)